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Abstract  
Introduction  
Prostate positional variability has been widely explored with seminal vesicle (SV) variability only 
coming into the forefront in recent years. While PTV margins and preparation protocols ameliorate 
the effects of bladder and rectum volume changes on prostate, studies on SV variation have looked 
at position only and not volume variability.  
 
Aim  
The aim of this study was to investigate whether interfraction volume variability of the seminal 
vesicles can exist in patients receiving radiotherapy to the prostate.  
 
Method  
SV variability was investigated by comparing 4 on-treatment Cone Beam Computer Tomography 
(CBCT) scans to a planning Computer Tomography (CT) image for two patients receiving prostate 
radiotherapy. Variation in volumes (cm3) were compared with intraobserver variation for each case.  
 
Results  
SV volume variability was seen in both patients with the largest change in volume being 78.38%. This 
variance was considerably (between 2 and 10 times) larger than the measured intraobserver 
variance  
 
Conclusion  
This study identified potential for daily SV volume variability in patients receiving prostate 
radiotherapy. Future large scale studies are warranted to identify the extent of this motion and 
potential clinical impact. Evidence-informed PTV margins and possible SV volume control protocols 
may need to be adopted.  
 
 
1 
 
Introduction 1 
The seminal vesicles (SV) sit posterior and inferior to the bladder and laterally to the ductus 2 
deferens. They are blind-ended tubes containing multiple pockets that are encased within 3 
connective tissue and are approximately 5-7cm in length.(1) The SVs are always included within the 4 
Clinical Target Volume (CTV) for intermediate and high-risk prostate cancers due to the higher risk of 5 
spread.(2)  6 
 7 
Movement of the prostate and SVs has been documented in several studies with a 2005 paper(3) first 8 
identifying a large distal SV displacement. It was the distal SVs which were also noted to have 9 
contributed to a greater variability in a 2012 study(4) which compared the dosimetric impact of 10 
displacement of the prostate and SVs in two groups; full SV (FSV) and proximal SV (PSV). They 11 
concluded that the SVs move independently of the prostate and that their displacement was 12 
greatest in the distal region of the SVs; meaning variability increases with distance from the 13 
prostate.  Even after correcting for changes in prostate position, the position of the SVs can still vary 14 
throughout treatment, compared to the position on the planning computed tomography (CT) scans.  15 
This poor correlation between SV and prostate position was confirmed by a 2008 fiducial marker 16 
study(5) which found variations in SV position to be independent of prostate fiducial markers. Despite 17 
these findings, it is common to prioritise prostate coverage over SV coverage because the prostate 18 
contains the largest portion of the Gross Tumour Volume (GTV). Since SV variation has a small 19 
impact on GTV match results, this can increase the simplicity and speed of on-line image matching.(3) 20 
 21 
Organ-at-risk (OAR) motion of bladder and rectum has been shown to exceed that of prostate and 22 
SV variability(3) meaning that prostate and SV deformation have long been considered to be second 23 
order effects behind OAR motion.(6-8) The evidence underpinning this, however, largely predates the 24 
introduction of image-guided radiotherapy (IGRT) and the resulting change in Planning Target 25 
Volume (PTV) margins.(9,10) A 2018 paper(11) concluded that OAR motion is not the main cause of 26 
prostate and SV motion although it can contribute. There is an element of compromise inherent in 27 
consideration of OAR motion with the PTV margin commonly being reduced posteriorly as per the 28 
widely accepted “conventional or hypofractionated high dose intensity modulated radiotherapy for 29 
prostate cancer” (CHHIP) trial protocol(9) to minimise rectal toxicity. Tumours often reside in the 30 
posterior peripheral region of the prostate; some authors have suggested that this factor along with 31 
reduction of margin size in this area can lead to tumour underdosage.(12)  32 
 33 
 
 
Apart from the posterior margin, traditionally, an equal PTV margin is placed around the prostate 34 
and SVs. However several authors(3-5) confirm that SV motion and deformation is independent of 35 
prostate motion and suggest that a separate PTV margin should be considered for the SVs to prevent 36 
underdosage. Evidence from a 2012 study(4) found that a 5mm margin was adequate for setup of 37 
PSV prostate patients and capable of achieving target V95 coverage in 90% of the patients (mean V95= 38 
99.6+/-0.8%). For “full” FSV patients this margin was insufficient leading to satisfactory V95 coverage 39 
in only 45% of patients (mean V95=97.9+/-2.4%). The study clearly identified the need for a separate 40 
margin for the prostate and seminal vesicles. 41 
 42 
Guidance from 2007(13) states that in patients with one or more risk factors, (Prostate Specific 43 
Antigen (PSA) >10, Gleason ≥ 7, > T2a, or percentage of positive biopsy > 50%) the risk of SV invasion 44 
is at least 15% and the seminal vesicles should be included in the target volume. Despite this, in 45 
clinical image-guided radiotherapy (IGRT) matching, the SV match is secondary to the prostate due 46 
to their reduced significance in terms of tumour control.  Although the evidence suggests that only 47 
the proximal SVs should be included in the target volume, some authors(13) have suggested that this 48 
evidence is contradictory and an insufficient basis for applying this practice to all patients. Currently 49 
there is little data that has considered SV position throughout prostate treatment, and in particular, 50 
no evidence related to SV volume variability.  Accordingly, the aim of this preliminary investigation 51 
was to investigate whether interfraction volume variability of the seminal vesicles could be present 52 
in patients receiving radiotherapy to the prostate. 53 
 54 
Methods 55 
Patient data sets  56 
This pilot study aimed to measure SV volumes on planning CT and IGRT conebeam (CBCT) images 57 
from 10 patients treated with radical prostate radiotherapy. Patients were chosen at random from 58 
those who had at least 4 on-treatment images taken between March and July 2018; at the centre in 59 
question this included patients enrolled in the PIVOTAL boost study.(14) Planning CT images were 60 
used as a reference, along with 4 other subsequent CBCT on-treatment images obtained using an on-61 
board imager (OBI) immediately after patient set-up. Prior to all scans, patients followed a 62 
preparation protocol including a full bladder and rectal enema. They were scanned in a head first 63 
supine position and immobilisation included omniboard, foot stocks, and headboard for each 64 
treatment.  65 
 66 
 
 
SV delineation 67 
Delineation of the SVs was carried out using treatment planning software by two users; a third-year 68 
radiotherapy student (user 1), and an experienced outliner (user 2). Credentialing was performed 69 
through repeat contouring of twelve training datasets to ensure intra-observer variability was 70 
minimised. Three repeats of SV contours (OL1, OL2, OL3) were performed for every acceptable data 71 
set; this enabled intra-observer variability to be calculated as well as average daily image variability 72 
for each patient. The inferior border of the SVs was difficult to distinguish on the CBCT images; 73 
therefore, in order to reduce variability due to unclear borders, the inferior border for all fractions 74 
was equalised. This was not necessary for the superior borders of the SVs as these were clearer to 75 
see and any subsequent variability would be due to volume variation above the defined level. 76 
 77 
Data analysis 78 
In this study the volume of each SV contour on each image was calculated; variance and standard 79 
deviation (SD) for intra-observer volume variability (IOVV) and interfraction volume variability (IFVV) 80 
were then calculated. Comparing these values allowed the impact of intra-observer variability(15) in 81 
outlining to be assessed. If IFVV was much greater than IOVV then it would indicate a true variation 82 
of volume.  83 
 84 
Ethical issues 85 
This study was classified as a “service evaluation” by the hospital Audit Committee; since 86 
retrospective anonymised patient data was utilised, consent was not mandated.  87 
 88 
Results 89 
Not all the gathered data had sufficient CBCT image quality to allow confidence in delineation of 90 
seminal vesicle volumes. The aim of this preliminary study was to identify if volume variation 91 
occurred in any prostate patients rather than to objectively quantify any potential effect. 92 
Accordingly the following two cases illustrate results confirming that this is a potential issue worthy 93 
of further quantitative study. Tables 1-4 present measured SV volumes per case (Case One and Two), 94 
user (User One and Two), fraction (a-e) and outlining (OL1-3).  95 
 96 
Noteworthy examples from this data are depicted in Figure 1 with overlaid contours highlighting 97 
volumetric and positional variation in Case One. In particular, a large volume variation can be seen in 98 
the bottom left image. In contrast, the bottom right image demonstrates an identical volume but 99 
clear positional variation. Variability of the mean outlined volumes is depicted graphically for each 100 
 
 
case and user in Figure 2. The data anonymisation process removed date stamps from the datasets 101 
so the chronological order of fractions is unknown. 102 
 103 
Summary of results 104 
It can be seen that for these selected cases there was considerable variation on SV volume which 105 
was much higher than intraobserver outlining variability, as seen in Table 5. The smallest and largest 106 
volumes for each patient and each user were used to calculate the maximum percentage increase in 107 
volume as seen in Table 6.  108 
 109 
Discussion  110 
Limitations 111 
There were several key limitations to this study. CBCT image quality for many of the sampled 112 
datasets was insufficient to outline SV volumes with confidence. The cases presented here were the 113 
exception and future work will need to draw on alternative imaging modalities to quantify variation 114 
with confidence. In addition, neither outliner in this study was a clinician; this was ameliorated to 115 
some extent through use of training, credentialing and repeat outlining. Expertise and confidence in 116 
outlining was felt to be more valuable than clinical interpretation for this phase of the study. 117 
Intraobserver variability was measured in order to eliminate this as an explanation for the findings. 118 
The accuracy of intraobserver variation has been estimated to be around 11% compared to accuracy 119 
of shape variation which was around 5%.(3) Time between intraobserver delineation seems to affect 120 
variability with short term intra-observer variability demonstrated to have no significant effect on 121 
treatment planning.(16) In this study, outlining was all performed within three days to minimise this 122 
potential impact. The small number of cases, while normally a limitation, in this case was a strength 123 
as the aim of the work was to identify the potential for this variation and not to measure it. The 124 
detection of two cases of volume variation within such a small sample strongly suggests a high 125 
overall incidence in the wider population.  126 
  127 
Causes of variability  128 
It is clear from the findings of this pilot study that in at least some cases, there is potential for 129 
interfractional SV variability in prostate patients. Future work intends to quantify the magnitude and 130 
frequency of these changes as well as identify impacting variables.  The shrinking effect of hormone 131 
therapy on the prostate, for example, is well documented.(11) yet none of the reported data includes 132 
SV volumes so it may be useful to study the effects of these in SV variability in future studies.  133 
 134 
 
 
Frequency of ejaculation has certainly been demonstrated to impact on SV volume in a number of 135 
studies on healthy individuals. (17,18) A 2017 magnetic-resonance image (MRI)-based study identified 136 
significant changes in 13 out of the 15 participants with mean volumes decreasing from 6.45 to 137 
4.80cm3.(17) This variation compares well with the variation identified in this study and would suggest 138 
that ejaculation whilst on radiotherapy treatment could be a factor impacting on SV volume and 139 
position. It is unknown how relevant these findings would be when applied to the more challenging 140 
prostate radiotherapy cohort and their well-documented sexual function issues.(19) Recent findings, 141 
however, indicate the therapeutic value of both medication and regular sexual activity  in penile 142 
rehabilition and long-term preservation of sexual function.(20)  143 
 144 
Clinical implications of variability  145 
It is unknown what the true incidence and extent of SV volume is amongst radiotherapy patients or, 146 
indeed, whether the variability is associated with clinical outcomes. It is already clear that SV motion 147 
independent of prostate position is a problem(4) and that existing PTV margins may not be 148 
appropriate in all cases with distal SV involvement. This preliminary work compounds these findings 149 
by detecting volume variation and, if significant, this may warrant individual derivation of PTV 150 
margins according to measured variability. Variability may impact on dosimetry and local control 151 
rates and future studies using daily MR imaging alongside monitoring and control of potential 152 
variables will aim to identify the true clinical implications of this study’s suggested variability.  153 
Conclusion  154 
This study concluded that there is potential for daily SV volume variability in patients receiving 155 
prostate radiotherapy, with up to 78.38% variation identified. More research is needed to determine 156 
how many and which patients this could impact on as well as to quantify the magnitude of variation 157 
and potential clinical impact. Future studies using MRI data, monitoring of variables and a larger 158 
number of patients are planned.  159 
 160 
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Tables 224 
 225 
Table 1: IFVV for Case One and User One 226 
 227 
Fraction OL1 OL2 OL3 Mean Variance  S.D 
a 4.4 4.4 3.7 4.17 0.11 0.33 
b 5.6 5.2 5.3 5.37 0.03 0.17 
c 5.3 5.6 5.7 5.53 0.03 0.17 
d 6.6 6.2 6.3 6.37 0.03 0.17 
e 5.6 5.2 5.5 5.43 0.03 0.17 
Mean 5.5 5.32 5.3 - - - 
Variance 0.50 0.35 0.75 - - - 
S.D. 0.70 0.59 0.87 - - - 
 228 
  229 
 
 
Table 2: IFVV for Case One and User Two 230 
 231 
Fraction OL1 OL2 OL3 Mean Variance S.D 
a 4.1 4.7 4.6 4.47 0.07 0.26 
b 4.8 4.9 4.5 4.73 0.03 0.17 
c 4.5 4.9 4.9 4.77 0.04 0.19 
d 6.4 4.9 5.3 5.53 0.40 0.63 
e 5.5 4.9 5.7 5.37 0.12 0.34 
Mean 5.06 4.86 5.0 - - - 
Variance 0.66 0.01 0.20 - - - 
S.D. 0.81 0.08 0.45 - - - 
 232 
  233 
 
 
Table 3: IFVV for Case Two and User One 234 
 235 
Fraction OL1 OL2 OL3 Mean Variance S.D 
a 9.3 8.5 9.5 9.10 0.19 0.43 
b 8.8 8.6 8.4 8.60 0.03 0.16 
c 8.1 7.4 8.1 7.87 0.11 0.33 
d 7.6 8.5 8.0 8.03 0.14 0.37 
e 8.6 8.7 9.0 8.77 0.03 0.17 
Mean 8.48 8.34 8.60 - - - 
Variance 0.34 0.23 0.32 - - - 
S.D. 0.58 0.48 0.57 - - - 
 236 
  237 
 
 
Table 4: IFVV for Case Two and User Two 238 
 239 
Fraction SV1 SV2 SV3 Mean Variance S.D 
a 9.60 9.10 8.70 9.13 0.14 0.37 
b 9.40 9.40 10.20 9.67 0.14 0.38 
c 6.10 6.10 6.80 6.33 0.11 0.33 
d 6.70 6.80 7.40 6.97 0.10 0.31 
e 7.50 8.50 8.50 8.17 0.22 0.47 
Mean 7.86 7.98 8.32 - - - 
Variance 1.99 1.69 1.37 - - - 
S.D. 1.41 1.30 1.17 - - - 
 240 
 241 
  242 
 
 
Table 5: Summary of SV volume variation. 243 
 244 
 Case One Case Two 
User One User Two User One User Two 
IOVV Mean variance 0.04 0.13 0.10 0.14 
Mean SD 0.20 0.32 0.29 0.37 
IFVV Mean variance 0.53 0.29 0.30 1.69 
Mean SD 0.72 0.45 0.54 1.30 
 245 
  246 
 
 
Table 6: Smallest and largest volumes recorded and percentage increases  247 
 248 
 Minimum  Maximum  % increase 
SVOL5, User 1 3.7cm-3 6.6cm3 78.38% 
SVOL5, User 2 4.1cm3 6.4cm3 56.10% 
SVOL6, User 1 7.4cm3 9.5cm3 27.03% 
SVOL6, User 2  6.1cm3 10.2cm3 67.21% 
 249 
 250 
 251 
  252 
 
 
Figure 1: Example variation in Case One 253 
  
Image a (blue) volume = 4.4cm3  
Image b (pink) volume = 5.6cm3 
Image a (blue) volume = 4.1cm3 
Image b (pink) volume = 4.8cm3 
  
Image a (yellow) volume = 3.7cm3 
Image d (green) volume = 6.6cm3 
Image a (blue) volume = 4.7cm3 
Image e (pink) volume = 4.9cm3 
 254 
 255 
  256 
 
 
Figure 2: Mean volume variability (in cm3) 257 
Case One User One Case One User Two 
  
Case Two User One Case Two User Two 
  
 258 
  259 
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Captions for illustrations 260 
 261 
Figure 1: Example variation in Case One 262 
Figure 2: Mean volume variability (in cm3) 263 
 264 
